Floatz logo

FLUOROURACILUM

Acinar Cell Adenocarcinoma of the Pancreas

Yale UniversitySmall moleculePhase 2Dormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Acinar Cell Adenocarcinoma of the Pancreas cohort.

Asset / SponsorPhaseRating
Eloxatin
Yale University
Phase 2BBB
Irinotecan
Artios Pharma Ltd
Phase 2BB
Metformin
Case Comprehensive Cancer Center
Phase 2BB
Carboplatin
National Cancer Institute (NCI)
Phase 2B
Bryostatin 1
National Cancer Institute (NCI)
Phase 2B

View all 34 →

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →